Wall Street brokerages forecast that Threshold Pharmaceuticals, Inc. (NASDAQ:THLD) will announce ($0.07) earnings per share for the current quarter, Zacks Investment Research reports. Zero analysts have provided estimates for Threshold Pharmaceuticals’ earnings. Threshold Pharmaceuticals posted earnings per share of ($0.08) during the same quarter last year, which suggests a positive year over year growth rate of 12.5%. The company is expected to issue its next quarterly earnings report on Monday, November 6th.
According to Zacks, analysts expect that Threshold Pharmaceuticals will report full-year earnings of ($0.29) per share for the current financial year. For the next year, analysts anticipate that the business will post earnings of ($0.39) per share. Zacks Investment Research’s earnings per share calculations are an average based on a survey of research firms that follow Threshold Pharmaceuticals.
Threshold Pharmaceuticals (NASDAQ:THLD) last announced its quarterly earnings results on Monday, July 31st. The biotechnology company reported $0.02 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.07) by $0.09. The business had revenue of $3 million for the quarter.
In related news, Director Jeffrey W. Bird purchased 510,703 shares of the firm’s stock in a transaction dated Thursday, June 1st. The stock was purchased at an average price of $0.57 per share, with a total value of $291,100.71. Following the completion of the purchase, the director now owns 919 shares of the company’s stock, valued at approximately $523.83. The acquisition was disclosed in a legal filing with the SEC, which is accessible through this link. Insiders own 12.97% of the company’s stock.
An institutional investor recently raised its position in Threshold Pharmaceuticals stock. FMR LLC increased its stake in shares of Threshold Pharmaceuticals, Inc. (NASDAQ:THLD) by 0.8% during the fourth quarter, according to its most recent disclosure with the Securities and Exchange Commission. The fund owned 397,754 shares of the biotechnology company’s stock after buying an additional 3,000 shares during the period. FMR LLC owned about 0.56% of Threshold Pharmaceuticals worth $175,000 as of its most recent SEC filing. Hedge funds and other institutional investors own 24.39% of the company’s stock.
Shares of Threshold Pharmaceuticals (NASDAQ:THLD) traded down 1.2859% on Friday, reaching $0.4913. The company had a trading volume of 436,631 shares. Threshold Pharmaceuticals has a 52 week low of $0.35 and a 52 week high of $1.48. The stock’s 50 day moving average is $0.45 and its 200 day moving average is $0.52. The firm’s market capitalization is $35.17 million.
ILLEGAL ACTIVITY NOTICE: This article was originally published by Community Financial News and is the property of of Community Financial News. If you are reading this article on another site, it was illegally stolen and republished in violation of U.S. and international trademark & copyright law. The legal version of this article can be viewed at https://www.com-unik.info/2017/08/19/zacks-analysts-expect-threshold-pharmaceuticals-inc-thld-to-announce-0-07-earnings-per-share-updated-updated.html.
Threshold Pharmaceuticals Company Profile
Threshold Pharmaceuticals, Inc is a clinical-stage biotechnology company. The Company is engaged in the discovery and development of therapeutic and diagnostic agents that selectively target tumor cells for the treatment of patients living with cancer. It is developing two therapeutic product candidates based on hypoxia-activated prodrug technology: evofosfamide and tarloxotinib.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
What are top analysts saying about Threshold Pharmaceuticals Inc.? - Enter your email address in the form below to receive our free daily email newsletter that contains the latest headlines and analysts' recommendations for for Threshold Pharmaceuticals Inc. and related companies.